


Development of diagnostics for COVID-19 has followed an accelerated timeline





To date: **37.4 million tests procured** across partners (Global Fund, GDF/StopTB, PAHO, UNDP, Unicef, WHO) with **over 27.1 million in transit or delivered**

Antigen RDT use recommended where PCR is unavailable or where prolonged turnaround times of PCR preclude clinical utility

-  **1 Respond to suspected outbreaks** in remote settings, institutions and semi closed communities
-  **2 Support outbreak investigations**, helping to screen at-risk individuals and rapidly isolate positive cases
-  **3 Monitor trends in disease incidence in communities**, particularly for essential workers and healthcare workers
-  **4** Where there is widespread community transmission, RDTs may be **used for early detection and isolation**, including asymptomatic contacts of cases

Initial price for RDTs is expected to be a ceiling price of 5 USD decreasing in 2021 to 2-3 USD



- ✓ Planning to procure and ship 20 million RDTs/month
- ✓ Access and Allocation framework has been developed (incorporates epidemiological and vulnerability factors)
- ✓ Diagnostic tests have been delivered to 134 countries to date

Any questions regarding Diagnostics procurement or supply chain, please reach out to our email: COVID19Enquiry-Diagnostics@who.int.

Dx Consortium	Resource location
Access and Allocation FAQs	https://www.who.int/publications/m/item/diagnostics-allocations-frequently-asked-questions
EUL listed products:	https://www.who.int/diagnostics_laboratory/201002_eul_sars_cov2_product_list.pdf?ua=1
Supply catalogue	https://www.who.int/publications/i/item/emergency-global-supply-chain-system-(covid-19)-catalogue